Glaxo Wellcome Lamictal
Executive Summary
New indication for use as adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients approved Aug. 24 as part of an NDA (20-764) for a new chewable dispersible tablet formulation of lamotrigine. A supplement to the original NDA (20-241/S-002) was also approved so that the new indication could be applied to the compressed tablet formulation as well